REHIRE Act

House Bill

H.R. 3093

119th Congress

REHIRE Act

In Committee

Introduced:Nov 25, 2025

Primary Sponsor

Donald S. Beyer Jr.

Representative

Democratic

VA-8

Cosponsors

18

Quick Stats

Policy Area

Health

Summary

This bill aims to make prescription drugs more affordable for Americans by requiring companies that receive federal funding for biomedical research or patents to set reasonable prices for the resulting products. It would tie U.S. prices to the median prices in Canada and several other high-income countries.

Latest Action

Referred to the Subcommittee on Health.

AI Summary

Plain-English explanation of this bill

This bill aims to make prescription drugs more affordable for Americans by requiring companies that receive federal funding for biomedical research or patents to set reasonable prices for the resulting products. It would tie U.S. prices to the median prices in Canada and several other high-income countries.

Last updated: 12/29/2025

Official Summary

Congressional Research Service summary

Affordable Pricing for Taxpayer-Funded Prescription Drugs Act of 2023 This bill requires companies that receive federal funding for research (or a license of the rights to a patent or regulatory test data) for a biomedical product or service to agree to set reasonable prices for the resulting biomedical product or service. The Department of Health and Human Services (HHS) must determine a reasonable price based on a formula that ensures the U.S. price for the product or service is not more than the median price for the product or service in Canada and six other reference countries with, based on specified criteria, large economies and high incomes. Companies entering these agreements also must report to HHS certain financial information related to the biomedical product or service involved.

Key Points

Main provisions of the bill

Requires companies that receive federal funding for biomedical research or patents to set reasonable prices for the resulting products.
Bases 'reasonable price' on a formula that ensures U.S. prices are not higher than the median price in Canada and six other reference countries.
Companies must report certain financial information related to the biomedical products to the Department of Health and Human Services.

How This Impacts Americans

Potential effects on citizens and communities

This bill would affect all Americans who rely on prescription drugs, as it would likely lead to lower out-of-pocket costs for many common medications. It would also impact pharmaceutical companies that receive federal funding, requiring them to justify their pricing and potentially reducing their profits on certain drugs.

Policy Areas

Primary Policy Area

Health

Related Subjects

Government information and archives

Health care costs and insurance

Prescription drugs

Scope & Jurisdiction

Jurisdiction Level

federal

Congressional Session

119th Congress

Citation Reference

3093, 119th Congress (2025). "REHIRE Act". Source: Voter's Right Platform. https://votersright.org/bills/118-hr-3093